12.01.07
Next Pharmaceuticals (NP), Salinas, CA, and The LaValle Metabolic Institute, Cincinnati, OH, have released the results of a clinical study on Seditol. Seven hundred and seventy-three people completed the open-label trial, which concluded that Seditol provides relaxation, promotes restful sleep and helps reduce fatigue due to lack of sleep. The LaValle Metabolic Institute conducted the study with Principal Investigator Jim LaValle, RPh, NMD, CCN. The primary objective was to study the efficacy and safety of Seditol while measuring its effects on quality of sleep.
The study was designed to be an open-label, single center clinical trial involving a minimum of 500 subjects who are patients of the clinic and reported having trouble falling asleep or staying asleep. Seven hundred and seventy-three people completed the study. More specifically, 718 of the participants reported that Seditol helped them relax; 680 reported Seditol helped them have a restful night’s sleep; and 696 reported Seditol helped reduce fatigue due to lack of sleep.
The study was designed to be an open-label, single center clinical trial involving a minimum of 500 subjects who are patients of the clinic and reported having trouble falling asleep or staying asleep. Seven hundred and seventy-three people completed the study. More specifically, 718 of the participants reported that Seditol helped them relax; 680 reported Seditol helped them have a restful night’s sleep; and 696 reported Seditol helped reduce fatigue due to lack of sleep.